{
  "id": "5e639d081af46fc130000014",
  "type": "list",
  "question": "What monoclonal antibody drugs are used to treat late stage melanoma?",
  "ideal_answer": "Nivolumab,  ipilimumab, vemurafenib, and dabrafenib are used to treat late stage melanoma",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29157311",
    "http://www.ncbi.nlm.nih.gov/pubmed/28118986",
    "http://www.ncbi.nlm.nih.gov/pubmed/24477411",
    "http://www.ncbi.nlm.nih.gov/pubmed/21957431",
    "http://www.ncbi.nlm.nih.gov/pubmed/23294221",
    "http://www.ncbi.nlm.nih.gov/pubmed/19018089",
    "http://www.ncbi.nlm.nih.gov/pubmed/18537753",
    "http://www.ncbi.nlm.nih.gov/pubmed/23262440",
    "http://www.ncbi.nlm.nih.gov/pubmed/30539467",
    "http://www.ncbi.nlm.nih.gov/pubmed/25125216",
    "http://www.ncbi.nlm.nih.gov/pubmed/25588084",
    "http://www.ncbi.nlm.nih.gov/pubmed/26105702",
    "http://www.ncbi.nlm.nih.gov/pubmed/17473208",
    "http://www.ncbi.nlm.nih.gov/pubmed/26313415",
    "http://www.ncbi.nlm.nih.gov/pubmed/24770508"
  ],
  "snippets": [
    {
      "text": " Nivolumab, a fully human monoclonal antibody against programmed cell death protein 1 (PD-1), has shown a survival benefit in an open-label phase II trial, and was the first PD-1 inhibitor to be approved worldwide. With a favorable side effect profile and ongoing trials in combination with extant therapies, nivolumab shows substantial potential to further augment the options for an effective treatment in malignant melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25588084",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Checkpoint blockade with ipilimumab provides long-term survival to a significant proportion of patients with metastatic melanoma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29157311",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29157311",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ate-stage cutaneous melanoma treated with vemurafenib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25125216",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ome of the drugs thus developed, such as vemurafenib and dabrafenib, show impressive responses in melanoma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23294221",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ipilimumab therapy for metastatic melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23262440",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Melanoma is the deadliest form of skin cancer. Ipilimumab, a novel immunotherapy, is the first treatment shown to improve survival in patients with metastatic melanoma in large randomized controlled studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23262440",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In 2011, new drugs were approved by the U.S. Food and Drug Administration, including peginterferon alfa-2b for patients with stage III disease, vemurafenib for patients with metastatic melanoma with the BRAF V600E mutation, and ipilimumab, a monoclonal antibody directed to the CTLA-4 T lymphocyte receptor, to combat metastatic melanoma in patients who do not have the BRAF V600E mutation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24770508",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Foremost among these was ipilimumab, a monoclonal antibody against the negative regulatory checkpoint molecule cytotoxic T-lymphocyte protein 4 (CTLA-4), which was the first drug in the management of metastatic melanoma to confer a survival benefit.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25588084",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "was ipilimumab, a monoclonal antibody against the negative regulatory checkpoint molecule cytotoxic T-lymphocyte protein 4 (CTLA-4), which was the first drug in the management of metastatic melanoma to confer a survival benefit. However, treatment is ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25588084",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TLA-4 monoclonal antibody ipilimumab has already been approved in advanced melanoma and two phase III trials evaluating ipilimumab in men with metastatic castrate-resistant prostate cancer are underway. A phase ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24477411",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26313415",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Ipilimumab, the first monoclonal antibody to be approved for the treatment of metastatic melanoma, showed significant improvements in durable response rates in patients and paved the way for next class of monoclonal antibodies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30539467",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18537753",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Nivolumab and pembrolizumab (formerly lambrolizumab), the two FDA-approved anti-programmed death-1 monoclonal antibodies, show highly durable response rates and long-term safety, validating the importance of the programmed cell death protein 1 pathway blockade for treatment of malignant melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26313415",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The anti-programmed cell death-1 (PD-1) monoclonal antibodies pembrolizumab and nivolumab have been contingently approved for the treatment of patients with advanced melanoma based on their durable response, high response rate, and favorable safety profile.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26105702",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Enhancement of the immune system by blockade of the cytotoxic T-lymphocyte associated antigen-4 by the monoclonal antibody ipilimumab is now approved by the United States Food and Drug Administration (FDA) for use in patients with unresectable melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21957431",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "ipilimumab, Nivolumab, vemurafenib, dabrafenib"
}